Interesting interview re Minicare system, page-5

So how would they overcome the below issues I wonder :

"We conducted a large survey around the world and see the key reason for this low adoption rate is mainly the perceived high cost for these tests, but also the low quality of the test results
compared to tests that are sent to the central lab."

Below from ADO Quarterly :

In October 2013 our client undertook a significant study using clinical samples to investigate
the performance of Mix&Go and to compare its performance with that achieved
conventionally. The results for Mix&Go were approaching those necessary for commercial
success. Since then a smaller study to assess progress using Mix&Go with clinical samples
was undertaken with a performance outcome approaching twice that achieved in October.

Refinements made since then through to the end of March are expected to deliver a range of
test performance levels that are comparable to many laboratory-based tests.
In early April activated particles, produced utilising what we consider to be our best (current)
approach, were sent for testing using the full panel of clinical samples held by our partner.
Results of this study are expected in the near future. A series of further tests have been jointly developed and will be undertaken, commencing early May, when several Anteo scientists will be working with the PoC 1 team in their laboratories.

Concurrently we have been discussing the likely parameters that would be covered by any
commercial interaction that results from these studies. There is a basic understanding on the
high level terms but the details remain dependant upon the outcome of the present analysis.